CN110603260B - Npra激动剂、组合物及其用途 - Google Patents

Npra激动剂、组合物及其用途 Download PDF

Info

Publication number
CN110603260B
CN110603260B CN201880028963.9A CN201880028963A CN110603260B CN 110603260 B CN110603260 B CN 110603260B CN 201880028963 A CN201880028963 A CN 201880028963A CN 110603260 B CN110603260 B CN 110603260B
Authority
CN
China
Prior art keywords
peptide
sequence
seq
cgmp
natriuretic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880028963.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110603260A (zh
Inventor
G·M·卡斯蒂洛
A·尼希莫托-阿施菲尔德
E·波罗汀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmain Corp
Original Assignee
Pharmain Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Corp filed Critical Pharmain Corp
Publication of CN110603260A publication Critical patent/CN110603260A/zh
Application granted granted Critical
Publication of CN110603260B publication Critical patent/CN110603260B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880028963.9A 2017-03-22 2018-03-21 Npra激动剂、组合物及其用途 Active CN110603260B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475147P 2017-03-22 2017-03-22
US62/475,147 2017-03-22
PCT/US2018/023491 WO2018175534A1 (en) 2017-03-22 2018-03-21 Npra agonists, compositions, and uses thereof

Publications (2)

Publication Number Publication Date
CN110603260A CN110603260A (zh) 2019-12-20
CN110603260B true CN110603260B (zh) 2023-11-07

Family

ID=63585777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880028963.9A Active CN110603260B (zh) 2017-03-22 2018-03-21 Npra激动剂、组合物及其用途

Country Status (15)

Country Link
US (1) US20200017567A1 (enExample)
EP (1) EP3601314A4 (enExample)
JP (2) JP7126270B2 (enExample)
KR (1) KR102714599B1 (enExample)
CN (1) CN110603260B (enExample)
AU (2) AU2018239352A1 (enExample)
BR (1) BR112019019720A2 (enExample)
CA (1) CA3056433A1 (enExample)
EA (1) EA201992226A1 (enExample)
IL (1) IL269388B2 (enExample)
MX (1) MX2019010960A (enExample)
MY (1) MY201165A (enExample)
PH (1) PH12019550163A1 (enExample)
SG (1) SG11201908580XA (enExample)
WO (1) WO2018175534A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972590A4 (en) * 2019-05-22 2023-06-14 Merck Sharp & Dohme LLC NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES
US20220281886A1 (en) 2019-05-22 2022-09-08 Merck Sharp Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
US20230416328A1 (en) * 2020-06-12 2023-12-28 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
IL298992A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and their methods for cancer treatment
CN120435308A (zh) 2022-10-21 2025-08-05 伊莱利利公司 长效利尿钠肽及其用途
AR130935A1 (es) 2022-11-02 2025-02-05 Novo Nordisk As Compuestos de cnp

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985722A (en) * 1973-12-12 1976-10-12 Ajinomoto Co., Inc. Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins
US5439887A (en) * 1992-02-12 1995-08-08 Roussel-Uclaf Peptide having antihypertensive activity free of vascoconstrictor activity
CN1199097A (zh) * 1996-12-27 1998-11-18 中国医学科学院基础医学研究所 Il－2或其衍生物与anp或其衍生物的融合基因、其三种蛋白质产物及应用、和包含该基因的载体及其构建方法
WO1999042472A1 (en) * 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system
WO2008154226A1 (en) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
WO2009067639A2 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
AU2011288919A1 (en) * 2011-02-23 2013-05-02 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4237375B2 (ja) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
BRPI0904622A2 (pt) * 2008-05-23 2016-06-21 Asubio Pharma Co Ltd peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma
HRP20161739T1 (hr) * 2009-05-20 2017-03-10 Biomarin Pharmaceutical Inc. VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa
CA2823066A1 (en) * 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US20120220528A1 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985722A (en) * 1973-12-12 1976-10-12 Ajinomoto Co., Inc. Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins
US5439887A (en) * 1992-02-12 1995-08-08 Roussel-Uclaf Peptide having antihypertensive activity free of vascoconstrictor activity
CN1199097A (zh) * 1996-12-27 1998-11-18 中国医学科学院基础医学研究所 Il－2或其衍生物与anp或其衍生物的融合基因、其三种蛋白质产物及应用、和包含该基因的载体及其构建方法
WO1999042472A1 (en) * 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system
WO2008154226A1 (en) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
WO2009067639A2 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
AU2011288919A1 (en) * 2011-02-23 2013-05-02 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
The natriuretic peptides and cardiometabolic health;Deepak K. Gupta 等;《Circ J.》;20160623;第79卷(第8期);第1647-1655页 *
脑钠肽与心血管疾病;张政;《中国临床实用医学》;20100108(第9期);第125-126页 *
脑钠肽和氨基末端脑钠肽在慢性阻塞性肺疾病所致肺动脉高压评估中的价值;韩孟生;《中国药物与临床》;20110228(第02期);第156-158页 *

Also Published As

Publication number Publication date
JP2022090049A (ja) 2022-06-16
CN110603260A (zh) 2019-12-20
EP3601314A1 (en) 2020-02-05
KR102714599B1 (ko) 2024-10-07
PH12019550163A1 (en) 2020-06-08
IL269388B2 (en) 2025-03-01
AU2025201270A1 (en) 2025-03-13
CA3056433A1 (en) 2018-09-27
JP7126270B2 (ja) 2022-08-26
MX2019010960A (es) 2020-01-20
SG11201908580XA (en) 2019-10-30
IL269388B1 (en) 2024-11-01
WO2018175534A1 (en) 2018-09-27
IL269388A (en) 2019-11-28
US20200017567A1 (en) 2020-01-16
BR112019019720A2 (pt) 2020-04-28
AU2018239352A1 (en) 2019-10-10
JP2020511494A (ja) 2020-04-16
EP3601314A4 (en) 2021-01-13
MY201165A (en) 2024-02-08
KR20190133201A (ko) 2019-12-02
EA201992226A1 (ru) 2020-02-12

Similar Documents

Publication Publication Date Title
CN110603260B (zh) Npra激动剂、组合物及其用途
CN103189389B (zh) 新的glp‑ⅰ类似物及其制备方法和用途
WO2009156481A1 (en) Pegylated bnp
IL264864B1 (en) Amylin analogs
JPH08504823A (ja) エンドセリン拮抗薬
WO2021093883A1 (zh) 双受体重激动剂化合物及其药物组合物
EP4442700A1 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
WO2003064462A1 (en) Peg-binding pth or peg-binding pth derivative
JP7751641B2 (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
KR20240109258A (ko) Glp-1 수용체와 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
KR20230121824A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
KR20230121823A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
JP2021176875A (ja) ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法
JP6005732B2 (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法
HK40017696B (zh) Npra激动剂、组合物及其用途
HK40017696A (en) Npra agonists, compositions, and uses thereof
EA044180B1 (ru) Агонисты npra, композиции и их использование
CN101356190A (zh) 用于抑制pf4和rantes相互作用的拮抗剂
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017696

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant